July 25, 2017 / 9:05 PM / 3 months ago

BRIEF-Helix Biopharma initiates enrollment in lung cancer drug study

July 25 (Reuters) - Helix Biopharma Corp

* Helix Biopharma Corp. initiates enrollment in the third dosing cohort of U.S. combination treatment study of its lung cancer drug candidate l-DOS47 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below